MedPharm Ltd., a contract developer of topical and transdermal pharmaceutical products, has taken the first steps to expand its manufacturing capacity in the U.S. to complement an existing manufacturing facility in the UK. MedPharm has obtained a facility in Durham, NC which will house liquid and semi-solid manufacturing and packaging capabilities with an initial capacity of up to 250kg. Located within a few miles of MedPharm’s current Center of Excellence in Research Triangle Park (RTP), this facility is expected to complete initial qualification by the start of Q4 2020.
 
The new site gives MedPharm’s U.S. based clients the opportunity to manufacture clinical batches and early stage development scale domestically. The facility is expected to further expand the number and type of manufacturing lines in the future based on market demand.
 
“MedPharm’s investment in this facility is a clear demonstration of our commitment to a global vision to expand services downstream towards manufacturing’ stated Eugene Ciolfi, president and chief executive officer, MedPharm. “MedPharm can now offer both clinical manufacture and formulation development for topical products in North America to complement similar services established for 20 years in the UK.”